NEW YORK (Reuters) -Health and wellness companies are embracing weight-loss drugs and building offerings around them in an ...

Wegovy and Ozempic remain on the FDA's shortages ... The request follows a similar move by Eli Lilly, which has asked for a ban on other parties making copies of its tirzepatide-based therapies ...

However, the pharma giant lowered its FY25 sales growth guidance owing to weaker-than-expected sales of its weight loss drug, Wegovy. Discover companies with rock-solid fundamentals in TipRanks' Smart ...